Color as an important biological variable in zebrafish models: Implications for translational neurobehavioral research
|
01.05.2021 |
de Abreu M.S.
Giacomini A.C.V.V.
Genario R.
dos Santos B.E.
Marcon L.
Demin K.A.
Galstyan D.S.
Strekalova T.
Amstislavskaya T.G.
Kalueff A.V.
|
Neuroscience and Biobehavioral Reviews |
10.1016/j.neubiorev.2020.12.014 |
0 |
Ссылка
© 2020 Elsevier Ltd Color is an important environmental factor that in multiple ways affects human and animal behavior and physiology. Widely used in neuroscience research, various experimental (animal) models may help improve our understanding of how different colors impact brain and behavioral processes. Complementing laboratory rodents, the zebrafish (Danio rerio) is rapidly emerging as an important novel model species to explore complex neurobehavioral processes. The growing utility of zebrafish in biomedicine makes it timely to consider the role of colors in their behavioral and physiological responses. Here, we summarize mounting evidence implicating colors as a critical variable in zebrafish models and neurobehavioral traits, with a particular relevance to CNS disease modeling, genetic and pharmacological modulation, as well as environmental enrichment and animal welfare. We also discuss the growing value of zebrafish models to study color neurobiology and color-related neurobehavioral phenomics, and outline future directions of research in this field.
Читать
тезис
|
Determination of the immunostimulatory drug—glucosoaminyl-muramyl-dipeptide—in human plasma using HPLC–MS/MS and its application to a pharmacokinetic study
|
01.12.2020 |
Moskaleva N.E.
Markin P.A.
Kuznetsov R.M.
Andronova T.M.
Appolonova S.A.
|
Biomedical Chromatography |
10.1002/bmc.4948 |
0 |
Ссылка
© 2020 John Wiley & Sons, Ltd. GMDP (glucosoaminyl-muramyl-dipeptide), a synthetic analog of the peptidoglycan fragment of the bacterial cell wall, is an active component of the immunomodulatory drug Licopid. But the pharmacokinetic parameters of GMDP in humans after oral administration have not been investigated yet. The present study aimed at developing and validating a sensitive LC–MS/MS method for the analysis of GMDP in human plasma. The sample was prepared by solid-phase extraction using Strata-X 33 μm polymeric reversed-phase 60 mg/3 mL cartridges Phenomenex (Torrance, CA, USA). The analytes were separated using an Acquity UPLC BEN C18 column, 1.7 μm 2.1 × 50 mm Waters (Milford, USA). GMDP and internal standard growth hormone releasing peptide-2 (pralmorelin) were ionized in positive electrospray ionization mode and detected in multiple reaction monitoring mode. The developed method was validated within a linear range of 50–3000 pg/mL for GMDP. Accuracy for all analytes, given as the deviation between the nominal and measured concentration and assay variability, ranged from 1.61 to 3.02% and from 0.89 to 1.79%, respectively, for both within- and between-run variabilities. The developed and validated HPLC–MS/MS method was successfully used to obtain the plasma pharmacokinetic profiles of GMDP distribution in human plasma.
Читать
тезис
|
Supply chain of the imported ginseng medicinal plant materials for the pharmaceutical industry of the Russian federation
|
01.01.2020 |
Litvinova T.
Glazkova I.
Levagina S.
Shalyapinа E.
Sheina A.
|
Uncertain Supply Chain Management |
10.5267/j.uscm.2019.7.002 |
0 |
Ссылка
© 2020 by the authors; licensee Growing Science, Canada. The article reviews methods of transportation for various types of imported medicinal plant materials of ginseng roots from China to the Russian Federation, with due consideration for risks. Logistic supply chains for ginseng roots have been developed and proposed based on the systemic method of research and the information analytical method. The optimal method for transportation of pharmaceutical substances of plant origin is chosen on the basis of the priority criteria for the cargo owner, as well as with due consideration for the peculiarities of the type of medicinal plant materials of ginseng roots.
Читать
тезис
|
Oncobox Method for Scoring Efficiencies of Anticancer Drugs Based on Gene Expression Data
|
01.01.2020 |
Tkachev V.
Sorokin M.
Garazha A.
Borisov N.
Buzdin A.
|
Methods in Molecular Biology |
10.1007/978-1-0716-0138-9_17 |
0 |
Ссылка
© Springer Science+Business Media, LLC, part of Springer Nature 2020. We describe here the Oncobox method for scoring efficiencies of anticancer target drugs (ATDs) using high throughput gene expression data. The method rationale, design, and validation are given along with the examples of its practical applications in biomedicine. The method is based on the analysis of intracellular molecular pathways activation and measuring expressions of molecular target genes for every ATD under consideration. Using Oncobox method requires collection of normal (control) expression profiles and annotated databases of molecular pathways and drug target genes. Both microarray and RNA sequencing profiles are acceptable, although the latter type of data prevails in the most recent applications of this technique.
Читать
тезис
|
Molecular Pathway Analysis of Mutation Data for Biomarkers Discovery and Scoring of Target Cancer Drugs
|
01.01.2020 |
Zolotovskaia M.
Sorokin M.
Garazha A.
Borisov N.
Buzdin A.
|
Methods in Molecular Biology |
10.1007/978-1-0716-0138-9_16 |
0 |
Ссылка
© Springer Science+Business Media, LLC, part of Springer Nature 2020. DNA mutations govern cancer development. Cancer mutation profiles vary dramatically among the individuals. In some cases, they may serve as the predictors of disease progression and response to therapies. However, the biomarker potential of cancer mutations can be dramatically (several orders of magnitude) enhanced by applying molecular pathway-based approach. We developed Oncobox system for calculation of pathway instability (PI) values for the molecular pathways that are aggregated mutation frequencies of the pathway members normalized on gene lengths and on number of genes in the pathway. PI scores can be effective biomarkers in different types of comparisons, for example, as the cancer type biomarkers and as the predictors of tumor response to target therapies. The latter option is implemented using mutation drug score (MDS) values, which algorithmically rank the drugs capacity of interfering with the mutated molecular pathways. Here, describe the mathematical basis and algorithms for PI and MDS values calculation, validation and implementation. The example analysis is provided encompassing 5956 human tumor mutation profiles of 15 cancer types from The Cancer Genome Atlas (TCGA) project, that totally make 2,316,670 mutations in 19,872 genes and 1748 molecular pathways, thus enabling ranking of 128 clinically approved target drugs. Our results evidence that the Oncobox PI and MDS approaches are highly useful for basic and applied aspects of molecular oncology and pharmacology research.
Читать
тезис
|
Modern ideas about juvenile dermatomyositis part 2: Activity assessment and treatment
|
01.09.2019 |
Podchernyaeva N.
Konevina M.
Tikhaya M.
|
Pediatriya - Zhurnal im G.N. Speranskogo |
10.24110/0031-403X-2019-98-5-135-146 |
0 |
Ссылка
© 2019, Pediatria Ltd. All rights reserved. In the article the authors present relevant information on the criteria for assessing the activity of juvenile dermatomyositis (JDM) and modern approaches to its treatment. In clinical practice, various scales are currently used to assess the overall JDM activity and severity of damage to various organs, primarily muscles and skin. The article provides modern recommendations for JDM treatment: The use of glucocorticosteroids, disease-modifying antirheumatic drugs (methotrexate, calcineurin inhibitors, cyclophosphamide, mycophenolate mofetil, azathioprine, hydroxychloroquine, intravenous immunoglobulin), genetically engineered drugs (rituximab, infliximab, adalimumab, golimumab, certolizumab, etanercept), as well as promising new drugs and methods of maintenance therapy. The modern JDM treatment algorithm is described.
Читать
тезис
|
Neurological, sensorimotor and cardiorespiratory alterations induced by methoxetamine, ketamine and phencyclidine in mice
|
01.10.2018 |
Ossato A.
Bilel S.
Gregori A.
Talarico A.
Trapella C.
Gaudio R.
De-Giorgio F.
Tagliaro F.
Neri M.
Fattore L.
Marti M.
|
Neuropharmacology |
|
5 |
Ссылка
© 2018 Elsevier Ltd Novel psychoactive substances are intoxicating compounds developed to mimic the effects of well-established drugs of abuse. They are not controlled by the United Nations drug convention and pose serious health concerns worldwide. Among them, the dissociative drug methoxetamine (MXE) is structurally similar to ketamine (KET) and phencyclidine (PCP) and was created to purposely mimic the psychotropic effects of its “parent” compounds. Recent animal studies show that MXE is able to stimulate the mesolimbic dopaminergic transmission and to induce KET-like discriminative and rewarding effects. In light of the renewed interest in KET and PCP analogs, we decided to deepen the investigation of MXE-induced effects by a battery of behavioral tests widely used in studies of “safety-pharmacology” for the preclinical characterization of new molecules. To this purpose, the acute effects of MXE on neurological and sensorimotor functions in mice, including visual, acoustic and tactile responses, thermal and mechanical pain, motor activity and acoustic startle reactivity were evaluated in comparisons with KET and PCP to better appreciate its specificity of action. Cardiorespiratory parameters and blood pressure were also monitored in awake and freely moving animals. Acute systemic administrations of MXE, KET and PCP (0.01–30 mg/kg i.p.) differentially alter neurological and sensorimotor functions in mice depending in a dose-dependent manner specific for each parameter examined. MXE and KET (1 and 30 mg/kg i.p.) and PCP (1 and 10 mg/kg i.p.) also affect significantly cardiorespiratory parameters, systolic and diastolic blood pressure in mice.
Читать
тезис
|
Comparison of Spectrophotometric and Chromatographic (HPLC) Procedures for Determining 3-Phenethylrhodanine Drug Substance with Anticancer Activity
|
01.05.2018 |
Novozhilova N.
Kutina N.
Kharitonov Y.
|
Pharmaceutical Chemistry Journal |
|
0 |
Ссылка
© 2018, Springer Science+Business Media, LLC, part of Springer Nature. A comparison of spectrophotometric and chromatographic (HPLC) procedures for determining 3-phenethylrhodanine (cyclo-2-phenethyldithiocarbanoylacetic acid, CPET) drug substance using experimental and computational statistical methods showed that both methods had good precision and accuracy and could be recommended as equivalent alternative methods for quantitative determination of CPET drug substance.
Читать
тезис
|
Dose–Response Effect of Antibodies to S100 Protein and Cannabinoid Receptor Type 1 in Released-Active Form in the Light–Dark Test in Mice
|
01.04.2018 |
Kardash E.
Ertuzun I.
Khakimova G.
Kolyadin A.
Tarasov S.
Wagner S.
Andriambeloson E.
Ivashkin V.
Epstein O.
|
Dose-Response |
|
1 |
Ссылка
© The Author(s) 2018. Earlier studies have shown that combination of antibodies to S100 protein and to cannabinoid receptor type 1 in released-active form (Brizantin) may possess anxiolytic properties and decrease nicotine dependence. Released-active form of antibodies is a novel approach that permits to modify natural functions of the target molecule (antigen) under investigation. The aim of the present study was to evaluate the anxiolytic-like effect of Brizantin in the light–dark test in mice, according to its ability to influence the number of entries into the lit compartment and the total time spent there. Three doses of Brizantin (2.5, 5, and 10 mL/kg) were compared with diazepam (1 mg/kg), placebo, and vehicle control. Anxiolytic-like effect of the tested drug was shown to be dose dependent, with an increasing trend from 2.5 to 10 mL/kg. Brizantin in its highest dose significantly increased studied behavioral parameters, although its effect was less pronounced than that of the reference drug diazepam (1 mg/kg).
Читать
тезис
|
Interchangeability Issues with Glaucoma Medicines Using Latanoprost as an Example
|
01.02.2018 |
Bunyatyan N.
Filippova O.
Romanov B.
Prokof’ev A.
|
Pharmaceutical Chemistry Journal |
|
0 |
Ссылка
© 2018, Springer Science+Business Media, LLC, part of Springer Nature. The possible interchangeability of eye drops was analyzed using glaucoma medicines containing latanoprost as examples. It was shown that the reference and generic drugs could be identical with respect to composition of active ingredients when manufactured from the same pharmaceutical substance but could differ in the excipient composition, in particular, have a different buffer and osmolality that could produce differences in their clinical effects. An analysis of the literature showed that the therapeutic efficacy and safety could vary for pharmaceutically equivalent drugs. The lack of therapeutic equivalence on the background of pharmaceutical equivalence could be caused by the use of different packaging and different dosing systems. Therefore, results from clinical trials must be compared to confirm the interchangeability of eye drops.
Читать
тезис
|
The mechanisms of development of pseudoallergic drug reactions and the prospects of personalized pharmacotherapy selection
|
01.01.2018 |
Kadyrova Z.
Teplyuk N.
|
Eksperimental'naya i Klinicheskaya Farmakologiya |
|
0 |
Ссылка
© Ruslania 2018. All rights reserved. Drug toxidermia is one of the most common skin diseases. Traditional therapy of drug toxidermia, which includes antihistamines and desensitizing agents, cannot stop manifestations of the pathological process in many cases, while the forced appointment of systemic glucocorticoids can lead to the development of un-desired complications. The review gives a detailed description of various mechanisms of drug toxidermia and provides information about the development of tests to identify patients with increased risk of drug toxidermia.
Читать
тезис
|
Hypnotics: Past, presence, future
|
01.01.2018 |
Churyukanov V.
Lemina E.
|
Eksperimental'naya i Klinicheskaya Farmakologiya |
|
0 |
Ссылка
© 2018 Izdatel'stvo Meditsina. All rights reserved. This article provides a short history of the creation of hypnotics, examines their mechanisms of action, and conducts a comparative analysis of the main groups of hypnotics such as barbiturates, benzodiazepines, "nonbenzodiazepine" benzodiazepine receptor agonists, melatonin receptor agonists, orexin receptor antagonists, histamine H1-receptor antagonists.
Читать
тезис
|
Opportunities of early treatment of acute respiratory viral infection in children
|
01.01.2018 |
Gеppe N.
Krylova N.
Eliseeva T.
Tyurina E.
Yablokova E.
|
Rossiyskiy Vestnik Perinatologii i Pediatrii |
|
0 |
Ссылка
© The authors team, 2018.All Rights Reserved. Purpose: to evaluate effectiveness of Oscillococcinum in the treatment of acute respiratory viral infections (ARVI) in children of different age groups. We observed 140 children from 1 to 14 years with mild to moderate-severe acute respiratory viral infection. 80 children (Group 1) were treated with Oscillococcinum, 60 children (Group 2) were treated symptomatically. Group 1 was divided into Subgroup 1А (40 children of 1-5 years old) and Subgroup 1B (40 children >5-14 years old). Group 2 was divided into Subgroup 2А (30 children of 1-5 years old) and Subgroup 2B (30 children >5-14 years old). The follow-up period was 7-10 days. Clinical efficacy was assessed by the severity of ARVI symptoms in scores from 0 to 2. All adverse events of the therapy were recorded. Also we evaluated disappearance of ARVI symptoms within 48 hours after the beginning of the therapy. Results: Oscillococcinum reduced the duration of ARVI in children of different age groups. During the first two days the symptoms of acute respiratory viral infection disappeared in 13 (16.3%) children of Group 1 receiving oscilococcinum and in 4 (6.7%) patients from Group 2 (OR = 2.7, 95 % CI 0.8-8.8, p <0.001). Conclusion: Oscillococcinum is an effective and safe drug to treat ARVI in children of different age groups.
Читать
тезис
|
Conservative treatment for patients with discogenic lumbosacral radiculopathy: Results of a prospective follow-up
|
01.01.2018 |
Ivanova M.
Parfenov V.
Isaikin A.
|
Nevrologiya, Neiropsikhiatriya, Psikhosomatika |
|
1 |
Ссылка
© Ima-Press Publishing House. All rights reserved. Surgical treatment as accelerated functional recovery for discogenic radiculopathy has been proven to have advantages over medical treatment, the efficiency of which remains debatable. Objective: to investigate the efficiency of combination conservative treatment in patients with discogenic lumbosacral radiculopathy. Patients and methods. Thirty patients (12 men and 18 women; mean age, 39.5±2.2 years) with discogenic lumbosacral radiculopathy confirmed by magnetic resonance imaging were followed up. All the patients underwent combination conservative treatment (epidural glucocorticoid administration, analgesic therapy, and motor mode correction). They were surveyed using questionnaires (numeric pain rating scale (NPRS), Oswestry disability index, Hospital Anxiety and Depression Scale, the 12-Item Short Form (SF-12) of Quality of Life (QoL) Questionnaire on admission to the clinic, at 7-14 days after treatment (pain intensity and functional status), and in the long-term period (at 3, 6 and 12 months) after discharge. At baseline, the patients were severely disabled due to pain syndrome. The average Oswestry index was 57.9±3.7%, the back and leg pain intensity scores were 6.5±0.6 and 6.9±0.5, respectively, as evidenced by NPRC. The majority of patients were found to have the combined musculoskeletal sources of pain, such as a myofascial component in 56.7% and sacroiliac joint dysfunction in 43.3%. In these cases, nonsteroidal anti-inflammatory drugs and muscle relaxants were additionally used. Results. The conservative treatment resulted in a statistically significant clinical improvement with a preserved positive effect in the long term: at 1 year, the average Oswestry index was equal to 16.6±3.9%, the back and leg pain intensity scores were 1.7±0.5 and 1.6±0.5, respectively, as shown by NPRC (p<0.001 vs baseline). Within a year, only one female patient required surgical treatment; regression of large extrusions and sequesters, the average initial size of which reached 11.1 mm, was observed in 9 cases. Conclusion. The findings reflect the efficiency of conservative treatment and the expediency of detecting mixed musculoskeletal disorders and their correction in discogenic radiculopathy.
Читать
тезис
|
A method for preparation of an endothelial cell monolayer sample from the blood vessel intima
|
01.01.2018 |
Solovyeva N.
|
Arkhiv Patologii |
|
0 |
Ссылка
© 2018, Media Sphera Publishing Group. All rights reserved. The paper describes the procedure to prepare endothelial cell monolayer samples from the vascular intima, which is suitable for studying various morphological processes. To obtain high-quality multicellular specimens, it is recommended to preliminarily remove excess tissue from the outside of the vessel and to free the intima; ways to dry the surface and to separate endothelial cells are examined. The paper gives the figures of specimens stained by the Romanowsky-Giemsa method and identifies factor VIII, an endothelial marker, and Chlamydia pneumoniae inclusions in the cytoplasm of endothelial cells.
Читать
тезис
|
Barrier drugs with prolonged release in dental practice
|
01.01.2018 |
Romanova Y.
Makeeva M.
|
Stomatologiia |
|
0 |
Ссылка
Pathological lesions associated with multiple causes (infections, physical, chemical and thermal agents) of oral mucosa are equally widespread in all spheres of dental practice. The actual importance of pharmaceutical therapy of lesions of oral mucosa is associated with the lack of reliable traditional topical drugs - ointments, gels, pastes, lacquers, discs - caused by their little efficiency associated with poor maintaining of permanent concentration, short contact period, discomfort and long-term treatment. All the mentioned facts caused the development of various pharmaceutical forms with prolonged activity with improved adhesion to oral mucosa, prolonged saving of useful properties and protecting the lesion from oral infection and external influences and reducing the intensity of painful sensations during mastication and mimics. These drugs form the group of barrier drugs and drugs with prolonged release of medicine of the wide specter. During all the time of existence this group of drugs has undergone and is still undergoing several changes targeted on improvement of adhesion and maintaining of constant concentration of medicine in the lesion and extension of indications for use. The development of new pharmaceutical forms is still continuing.
Читать
тезис
|
Current management tactics for patients with dementia
|
01.01.2018 |
Medvedeva A.
Kosivtsova O.
Makhinov K.
|
Nevrologiya, Neiropsikhiatriya, Psikhosomatika |
|
0 |
Ссылка
© 2018 Ima-Press Publishing House. All rights reservbed. Dementia develops as a result of continuous long-term progression of less severe cognitive impairment (CI). Social and psychological methods (neurocognitive stimulation and neurocognitive training) are the mainstay of treatment for dementia. At the moment, there are no drugs both to cure dementia and to stop the degeneration of nerve tissue. Modern pharmacotherapy for dementia aims to maintain cognitive functions in the patient for as long as possible and to slow down disability, thus ensuring higher living standards. CI therapy most often consists of compensation for cognitive defect. Among the whole variety of pharmacological agents, the effective drugs to treat dementia are only two groups, such as acetylcholinesterase inhibitors and N-methyl-D-aspartate (NMDA) glutamate receptor antagonists. Atypical neuroleptics are employed for the treatment of psychotic disorders; antidepressants from a group of selective serotonin reuptake inhibitors are for depression. Cognitive behavioral therapy and cognitive stimulation deserve special attention. A high educational level and physical, social, and intellectual and activities can prevent dementia.
Читать
тезис
|
Blood pressure variability in hypertension associated with coronary heart disease: Prognostic value and management approaches
|
01.01.2018 |
Ostroumova O.
Kochetkov A.
Guseva T.
|
Arterial Hypertension (Russian Federation) |
|
2 |
Ссылка
© 2018 All-Russian Public Organization Antihypertensive League. All rights reserved. The review discusses the role of blood pressure variability as a novel risk factor and its prognostic value in hypertension associated with the coronary artery disease. We discuss the modern approaches to calculation of blood pressure variability, its classification. The choice of antihypertensive drugs based on the blood pressure variability is discussed considering hypertension associated with coronary artery disease. We pay special attention to angiotensin enzyme converting inhibitors and calcium channel blockers, as well as their combinations. We present the evidence of the effects of perindopril and amlodipine and their fixed combination on the blood pressure variability and the decrease in cardiovascular risk in hypertension associated with coronary artery disease.
Читать
тезис
|
Day-by day blood pressure variability: methodological aspects; prognostic value, effects of antihypertensive therapy
|
01.01.2018 |
Ostroumova O.
Borisova E.
Guseva T.
Temirbulatov I.
|
Kardiologiya |
|
0 |
Ссылка
© 2018 Media Sphera Publishing Group. All rights reserved. In this article we present problems of prognostic value of day-by-day blood pressure (BP) variability, its role in development and progression of damage of target organs in arterial hypertension, and impact on risk of cardiovascular, cerebral-vascular complications, and mortality. We also discuss methodological aspects of assessment of day-by-day BP variability. The article contains literature data on effects of antihypertensive therapy on variability of home BP, and consideration of evidence base of possibilities of the fixed amlo-dipine/perindopril combination for lowering day-by-day BP variability.
Читать
тезис
|
Cognitive impairment in patients with type 2 diabetes mellitus: prevalence, pathogenetic mechanisms, the effect of antidiabetic drugs
|
01.01.2018 |
Ostroumova O.
Surkova E.
Chikh E.
Rebrova E.
Borisov M.
|
Diabetes Mellitus |
|
3 |
Ссылка
© 2018 Russian Association of Endocrinologists. All rights reserved. In recent years, a large amount of data has been accumulated on the relationship between cognitive impairment, dementia and diabetes mellitus. This article presents an overview of modern literature, including the definition of cognitive functions, the modern classification of cognitive impairment, pathogenetic mechanisms of diabetes mellitus influence on the development of cognitive impairment and dementia (neurogenesis, integrity of the blood-brain barrier, systemic inflammatory reactions, hyper- And hypoglycemia, insulin resistance, vascular dysfunction of the microvasculature and increase in glucocorticosteroids). The influence of anti-diabetic medications on cognitive functions has been examined in detail: insulin preparations, oral hypoglycemic agents of the biguanide group (metformin), thiazolidinediones (rosiglitazone and pioglitazone), sulfonylurea derivatives (glycazide, glipizide), a-glucosidase (acarbose) inhibitors, incretin-directed therapy (receptor agonists glucan-like peptide (exenatide and liraglutide) and inhibitors of dipeptidylpeptidase type 4 (sitagliptin, vildagliptin and alogliptin)), sodium glucose inhibitors cotransporter type 2. The data demonstrating a multidirectional effect on the cognitive functions of various antidiabetic drugs is presented, the possible influence on the rate of progression of cognitive impairment and the risk of dementia of intensive control of plasma glucose level in comparison with the standard decrease in patients with type 2 diabetes is analyzed.
Читать
тезис
|